Baxano Surgical Inc  

(Public, NASDAQ:BAXS)   Watch this stock  
Find more results for Matthew Ainsworth
0.977
+0.007 (0.74%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.96 - 0.99
52 week 0.92 - 2.50
Open 0.98
Vol / Avg. 257,369.00/625,654.00
Mkt cap 46.09M
P/E     -
Div/yield     -
EPS -0.84
Shares 47.17M
Beta 0.54
Inst. own 57%
May 5, 2014
Q1 2014 Baxano Surgical Inc Earnings Release (Estimated) Add to calendar
Apr 17, 2014
Baxano Surgical Inc Annual Shareholder Meeting
Mar 11, 2014
Baxano Surgical Inc at Canaccord Genuity's Musculoskeletal Conference
Mar 6, 2014
Q4 2013 Baxano Surgical Inc Earnings Conference Call
Mar 6, 2014
Q4 2013 Baxano Surgical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -141.66% -172.35%
Operating margin -140.71% -171.15%
EBITD margin - -138.00%
Return on average assets -67.29% -78.84%
Return on average equity -101.91% -126.62%
Employees 139 -
CDP Score - -

Address

Suite 230 110 Horizon Drive
RALEIGH, NC 27615
United States - Map
+1-919-8000020 (Phone)
+1-800-2535177 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Baxano Surgical Inc, formerly TranS1 Inc., is a medical device company focused on designing, developing and marketing products that implement its approach to treat degenerative conditions of the spine affecting the lower lumbar region. It develops its pre-sacral approach to allow spine surgeons to access and treat intervertebral spaces without compromising important surrounding soft tissue, nerves and bone structures. As of December 31, 2011, the Company was marketing the AxiaLIF family of products for single and multilevel lumbar fusion, the Vectre and Avatar lumbar posterior fixation systems and Bi-Ostetic bone void filler, a biologics product. All of the Company�s AxiaLIF products are delivered using its pre-sacral approach. It generates revenue from the sales of itsimplants and disposable surgical instruments. It has two distinct sales methods.

Officers and directors

Paul A. LaViolette Independent Chairman of the Board
Bio & Compensation  - Reuters
Kenneth Reali President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Timothy M. Shannon Chief Financial Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Greg D. Slusser Vice President - Commercial Operations
Age: 52
Bio & Compensation  - Reuters
Greg Welsh Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Mukesh Ramchandani Vice President and General Manager, International
Age: 47
Bio & Compensation  - Reuters
Matthew Pickens Vice President - Marketing and Reimbursement
Bio & Compensation  - Reuters
Stephanie M. Fitts Ph.D. Vice President - Regulatory, Quality and Compliance
Age: 47
Bio & Compensation  - Reuters
Stephen D. Ainsworth Ph.D. Vice President - Research & Development
Age: 43
Bio & Compensation  - Reuters
Jeffrey Fischgrund M.D. Independent Director
Age: 52
Bio & Compensation  - Reuters